An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Hypogonadotropic hypogonadism (HH) in men results in insufficient testicular function and deficiencies in testosterone and spermatogenesis. Combinations of human chorionic gonadotropin (hCG) and recombinant follicle-stimulating hormone (recFSH) have been successful in the treatment of HH. Corifollitropin alfa is a long-acting FSH-analog with demonstrated action in women seeking infertility care. The aim of this study was to investigate the efficacy and safety of corifollitropin alfa combined with hCG to increase testicular volume and induce spermatogenesis in men with HH. This was a Phase III, multi-center, open-label, single-arm trial of corifollitropin alfa in azoospermic men aged 18 to 50 years with HH. After 16 weeks of pretreatment of 23 subjects with hCG alone, 18 subjects with normalized testosterone (T) levels who remained azoospermic entered the 52-week combined treatment phase with hCG twice-weekly and 150 μg corifollitropin alfa every other week. The increase in testicular volume (primary efficacy endpoint) and induction of spermatogenesis resulting in a sperm count ≥1 × 106/mL (key secondary efficacy endpoint) during 52 weeks of combined treatment were assessed. Safety was evaluated by the presence of anti-corifollitropin alfa antibodies and the occurrence of adverse events (AEs). Mean (±SD) testicular volume increased from 8.6 (±6.09) mL to 17.8 (±8.93) mL (geometric mean fold increase, 2.30 [95% CI: 2.03, 2.62]); 14 (77.8%) subjects reached a sperm count ≥1 × 106/mL. No subject developed confirmed anti-corifollitropin alfa antibodies during the trial. Treatment was generally well tolerated. Corifollitropin alfa 150 μg administrated every other week combined with twice-weekly hCG for 52 weeks increased testicular volume significantly, and induced spermatogenesis in >75% of men with HH who had remained azoospermic after hCG treatment alone. ClinicalTrials.gov: NCT01709331 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“rhFSH has a short half-life which means it has to be injected 3 times a week.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“Corifollitropin alfa is a FSH-analog with a similar pharmacodynamic profile as rhFSH but a longer half-life. Therefore, the frequency of corifollitropin alfa injections can be diminished to once every week [33].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buchter, D., Behre, H., Kliesch, S., & Nieschlag, E. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1390298 · Cited by 269
Self-citationHypogonadotropic Hypogonadism Revisited
Fraietta, R., Zylberstejn, D. S., & Esteves, S. C. (2013) · Clinics · doi:10.6061/clinics/2013(sup01)09 · Cited by 248
Devroey, P., Boostanfar, R., Koper, N. P., Mannaerts, B. M. J. L., IJzerman-Boon, P. C., Fauser, B. C. J. M., & on behalf of the ENGAGE Investigators (2009) · Human Reproduction · doi:10.1093/humrep/dep291 · Cited by 217
Fauser, B. C. J. M., Mannaerts, B. M. J. L., Devroey, P., Leader, A., Boime, I., & Baird, D. T. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmn065 · Cited by 161
Rohayem, J., Hauffa, B. P., Zacharin, M., Kliesch, S., Zitzmann, M., & the “German Adolescent Hypogonadotropic Hypogonadism Study Group” (2017) · Clinical Endocrinology · doi:10.1111/cen.13164 · Cited by 148
Liu, P. Y., Turner, L., Rushford, D., McDonald, J., Baker, H. W. G., Conway, A. J., & Handelsman, D. J. (1999) · Human Reproduction · doi:10.1093/humrep/14.6.1540 · Cited by 139
Burgues, S., & Calderon, M. D. (1997) · Human Reproduction · doi:10.1093/humrep/12.5.980 · Cited by 124
First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males
Bouloux, P. (2001) · Human Reproduction · doi:10.1093/humrep/16.8.1592 · Cited by 115
Self-citationBouloux, P. G., Nieschlag, E., Burger, H. G., Skakkebaek, N. E., Wu, F. C. W., Handelsman, D. J., Baker, G. H. W., Ochsenkuehn, R., Syska, A., McLachlan, R. I., et al. (2003) · Journal of Andrology · doi:10.1002/j.1939-4640.2003.tb02712.x · Cited by 107
Self-citationCorifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women
1 (2010) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2010.03.019 · Cited by 95
Research works printed but not linked: 2
- Rohayem J, Zitzmann M, Nieschlag E. Congenital hypogondotropic hypogonadism and Kallmann’s syndrome. Reference Module in Biomedical Sciences. Elsevier 12-Dec-15; doi: 10.1016/B978-0-12-801238–3.98874–3 . · DOI
- WHO Laboratory Manual for the Examination and Processing of Human Sperm, 5th edition. Geneva: World Health Organisation; 2010.
Cited by
Santi, D., Crépieux, P., Reiter, E., Spaggiari, G., Brigante, G., Casarini, L., Rochira, V., & Simoni, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041014 · Cited by 164
Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism
Jayasena, C. N., Anderson, R. A., Llahana, S., Barth, J. H., MacKenzie, F., Wilkes, S., Smith, N., Sooriakumaran, P., Minhas, S., Wu, F. C. W., et al. (2022) · Clinical Endocrinology · doi:10.1111/cen.14633 · Cited by 147
Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
Ide, V., Vanderschueren, D., & Antonio, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010021 · Cited by 101
Li, K.-P., Yang, X.-S., & Wu, T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.810242 · Cited by 79
“On the other hand, some studies have reported that hormones and SERMs increased sperm quality (66).”
BackgroundGonadotropins and Their Analogs: Current and Potential Clinical Applications
Anderson, R. C., Newton, C. L., Anderson, R. A., & Millar, R. P. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00052 · Cited by 61
Metadata
- Authors
- Nieschlag, E., Bouloux, P.-M. G., Stegmann, B. J., Shankar, R. R., Guan, Y., Tzontcheva, A., McCrary Sisk, C., & Behre, H. M.
- Affiliations
- University Hospital Münster (DE)
- The Royal Free Hospital (GB)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University Hospital in Halle (DE)
- Corresponding author
- Nieschlag, Eberhard
- ORCID
- Venue
- Reproductive Biology and Endocrinology
- Published
- 2017-03-07
- Volume
- 15
- Issue
- 1
- Pages
- 17-17
- ISSN
- 1477-7827 (ISSN-L)
- PMC
- PMC5341390
- OpenAlex
- W2593671636
- Cited by
- 45
- References
- 16
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 4 · 2020: 5 · 2019: 5 · 2018: 3 · 2017: 1
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Reproductive Biology and Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Merck
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Health Sciences › Medicine › Reproductive Medicine › Sperm and Testicular Function
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- corifollitropin alfa, hypogonadotropic hypogonadism, azoospermia, human chorionic gonadotropin, spermatogenesis, testicular volume, androgen deficiency, male infertility, anti-drug antibodies, treatment efficacy and safety, combined hormone therapy, spermatogenesis induction
- MeSH terms
- Adult, Drug Administration Schedule, Chorionic Gonadotropin, Humans, Hypogonadism, Male, Middle Aged, Organ Size, Spermatogenesis, Testis, Treatment Outcome, Follicle Stimulating Hormone, Human, Azoospermia, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism. https://app.cochat.ai/papers/10.1186/s12958-017-0232-y
- The paper
- Nieschlag, E., Bouloux, P.-M. G., Stegmann, B. J., Shankar, R. R., Guan, Y., Tzontcheva, A., McCrary Sisk, C., & Behre, H. M. (2017). An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism. Reproductive Biology and Endocrinology. https://doi.org/10.1186/s12958-017-0232-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.